Sirio Pharma Co., Ltd. Class A

Sirio Pharma Co., Ltd. Class A

SSZSE:300791
16.90
CNY
-0.46
(-2.65%)
0.00EPS
53.29P/E
5.67BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A carries a market capitalization of 5.67B, placing it among publicly traded companies globally. Its enterprise value stands at 6.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.67B
Enterprise Value6.64B

Important Dates

Sirio Pharma Co., Ltd. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A has 308.23M shares outstanding.

Shares Outstanding308.23M

Valuation Ratios

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 53.29. The price-to-sales ratio is 1.40, and the price-to-book ratio stands at 1.84.

PE Ratio53.29
PS Ratio1.40
PB Ratio1.84
P/TBV Ratio2.58

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.64B versus a market cap of 5.67B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.64

Financial Position

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.81, indicating elevated leverage, while an interest coverage ratio of -0.10 demonstrates limited ability to service its debt obligations.

Current Ratio1.06
Quick Ratio0.41
Debt / Equity63.81
Debt / EBITDA-208.07
Interest Coverage-0.10

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.45M in revenue per employee across its workforce of 2,776.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.45M
Employee Count2,776.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Sirio Pharma Co., Ltd. Class A recorded an income tax benefit of -13.66M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -12.94M and 106.13M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-13.66M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Sirio Pharma Co., Ltd. Class A's stock has declined approximately 31.74% over the past 52 weeks. The 50-day moving average sits at 17.52, while the 200-day moving average is 18.65.

52-Week Price Change-31.74%
50-Day Moving Average17.52
200-Day Moving Average18.65

Income Statement

CNY

Over the twelve months ended September 30, 2026, Sirio Pharma Co., Ltd. Class A generated 4.04B in revenue and converted that into 106.13M in net income, yielding earnings per share of 0.00. EBITDA reached -9.44M, while operating income came in at 340.65M.

Revenue4.04B
Gross Profit1.29B
Operating Income340.65M
Pretax Income-12.94M
Net Income106.13M
EBITDA-9.44M
EBIT-9.44M

Balance Sheet

CNY

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A holds 989.75M in cash and equivalents against 1.96B in total debt, resulting in a net debt position of -301.71M. Total book value stands at 3.09B, with working capital of 140.92M providing operational flexibility.

Cash & Cash Equivalents989.75M
Total Debt1.96B
Net Debt-301.71M
Equity (Book Value)3.09B
Book Value Per Share10.02
Working Capital140.92M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-372.22M

Margins

Over the twelve months ended September 30, 2026, Sirio Pharma Co., Ltd. Class A posted a gross margin of 31.95, reflecting its pricing power and cost economics. The operating margin of 8.44 and net profit margin of 2.63 provide insight into operational efficiency.

Gross Margin31.95
Operating Margin8.44
Pretax Margin-0.32
Profit Margin2.63
EBITDA Margin-0.23

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Sirio Pharma Co., Ltd. Class A paid dividends of 0.26 per share. The dividend payout ratio of -76.75 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -5.10, meaning Sirio Pharma Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.26
Payout Ratio-76.75
Shareholder Yield-5.10

Stock Splits

Sirio Pharma Co., Ltd. Class A's most recent stock split took place on May 27, 2025 with a 10:13 split ratio.

Last Split Date5/27/2025
Split Ratio10:13

Scores

As of September 30, 2026, Sirio Pharma Co., Ltd. Class A has an Altman Z-Score of 2.62, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.62